CardiaTec.ai: Advancing Cardiovascular Research Through AI-Powered Multiomics Insights

CardiaTec.ai is a pioneering TechBio company dedicated to unraveling the complexities of cardiovascular disease by leveraging advanced computational modeling on multiomics data from human cardiac tissue. Backed by a network of 65 hospitals and rooted in research from the University of Cambridge’s Han Lab, it is building the world’s largest human cardiac tissue multiomics database. This powerful platform accelerates the discovery and development of novel therapeutics, combining genomics, epigenomics, transcriptomics, and proteomics data with cutting-edge AI to drive breakthroughs in heart health. Recognized as AI Startup of the Year and featured in leading publications like TechCrunch and the Guardian, CardiaTec.ai stands at the forefront of AI-driven drug discovery in cardiology.

Key Features:

• Multiomics Data Integration: Combines genomics, epigenomics, transcriptomics, and proteomics from human cardiac tissue.
• AI-Powered Computational Modeling: Utilizes state-of-the-art algorithms to decode disease biology at a molecular level.
• Large-Scale Human Tissue Database: Building the most comprehensive database of its kind, supported by 65 hospitals.
• Therapeutic Discovery Engine: Enables rapid identification and development of new cardiovascular treatments.
• Scientific Validation & Expertise: Developed by leading researchers and recognized by prestigious institutions and awards.
• Industry Leadership & Recognition: Member of the BioIndustry Association’s advisory committee and honored as AI Startup of the Year.

Pricing: CardiaTec.ai operates under a subscription-based model tailored for research and pharmaceutical partners, with pricing available upon request.

Conclusion: CardiaTec.ai is a transformative force in cardiovascular research, combining deep biological insight with advanced AI to unlock new therapies and redefine the future of heart disease treatment.